Literature DB >> 19694748

Updated study on risk of cholestatic liver disease and flucloxacillin.

Lin Li, Hershel Jick, Susan S Jick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19694748      PMCID： PMC2767292          DOI： 10.1111/j.1365-2125.2009.03454.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  9 in total

1.  Improving drug use: a case study of events which led to changes in use of flucloxacillin in Australia.

Authors:  E E Roughead; A L Gilbert; J G Primrose
Journal:  Soc Sci Med       Date:  1999-03       Impact factor: 4.634

Review 2.  Drug-induced cholestasis.

Authors:  Cynthia Levy; Keith D Lindor
Journal:  Clin Liver Dis       Date:  2003-05       Impact factor: 6.126

3.  Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.

Authors:  Stefan Russmann; James A Kaye; Susan S Jick; Hershel Jick
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

4.  Flucloxacillin and cholestatic hepatitis.

Authors:  H Jick; L E Derby; A D Dean; D A Henry
Journal:  Med J Aust       Date:  1994-04-18       Impact factor: 7.738

5.  Prolonged hepatic cholestasis after flucloxacillin therapy.

Authors:  I B Turner; R P Eckstein; J W Riley; M R Lunzer
Journal:  Med J Aust       Date:  1989 Dec 4-18       Impact factor: 7.738

6.  Cholestatic hepatitis associated with flucloxacillin.

Authors:  L E Derby; H Jick; D A Henry; A D Dean
Journal:  Med J Aust       Date:  1993-05-03       Impact factor: 7.738

7.  Flucloxacillin-induced cholestatic liver damage.

Authors:  F Bengtsson; C H Florén; I Hägerstrand; C Söderström; T Aberg
Journal:  Scand J Infect Dis       Date:  1985

8.  Prolonged severe cholestasis induced by oxacillin derivatives. A report on two cases.

Authors:  P Tauris; N F Jørgensen; C M Petersen; K Albertsen
Journal:  Acta Med Scand       Date:  1985

9.  Increasing hospitalizations and general practice prescriptions for community-onset staphylococcal disease, England.

Authors:  Andrew Hayward; Felicity Knott; Irene Petersen; David M Livermore; Georgia Duckworth; Amir Islam; Anne M Johnson
Journal:  Emerg Infect Dis       Date:  2008-05       Impact factor: 6.883
  9 in total
  6 in total

1.  Communicating about potential drug harms: safety implications for patients.

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 2.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

Review 3.  Whole genome association studies in complex diseases: where do we stand?

Authors:  Anna C Need; David B Goldstein
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

4.  Optimising case detection within UK electronic health records: use of multiple linked databases for detecting liver injury.

Authors:  Kevin Wing; Krishnan Bhaskaran; Liam Smeeth; Tjeerd P van Staa; Olaf H Klungel; Robert F Reynolds; Ian Douglas
Journal:  BMJ Open       Date:  2016-09-02       Impact factor: 2.692

Review 5.  Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man.

Authors:  Sanja Dragovic; Nico P E Vermeulen; Helga H Gerets; Philip G Hewitt; Magnus Ingelman-Sundberg; B Kevin Park; Satu Juhila; Jan Snoeys; Richard J Weaver
Journal:  Arch Toxicol       Date:  2016-09-22       Impact factor: 5.153

6.  Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study.

Authors:  Kevin Wing; Krishnan Bhaskaran; Louise Pealing; Adrian Root; Liam Smeeth; Tjeerd P van Staa; Olaf H Klungel; Robert F Reynolds; Ian Douglas
Journal:  J Antimicrob Chemother       Date:  2017-09-01       Impact factor: 5.790
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.